Cargando…

Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)

OBJECTIVE: The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat indivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kravchenko, Olga V, Boyce, Richard D, Gomez-Lumbreras, Ainhoa, Kocis, Paul T, Villa Zapata, Lorenzo, Tan, Malinda, Leonard, Charles E, Andersen, Kathleen M, Mehta, Hemalkumar, Alexander, G Caleb, Malone, Daniel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806069/
https://www.ncbi.nlm.nih.gov/pubmed/36581417
http://dx.doi.org/10.1136/bmjopen-2022-066846
_version_ 1784862454925230080
author Kravchenko, Olga V
Boyce, Richard D
Gomez-Lumbreras, Ainhoa
Kocis, Paul T
Villa Zapata, Lorenzo
Tan, Malinda
Leonard, Charles E
Andersen, Kathleen M
Mehta, Hemalkumar
Alexander, G Caleb
Malone, Daniel C
author_facet Kravchenko, Olga V
Boyce, Richard D
Gomez-Lumbreras, Ainhoa
Kocis, Paul T
Villa Zapata, Lorenzo
Tan, Malinda
Leonard, Charles E
Andersen, Kathleen M
Mehta, Hemalkumar
Alexander, G Caleb
Malone, Daniel C
author_sort Kravchenko, Olga V
collection PubMed
description OBJECTIVE: The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE. DESIGN: We used nested case–control study design. SETTING: This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repository for COVID-19 in the USA. PARTICIPANTS: Study participants were adults over 18 years who were exposed to a DOAC for 10 or more consecutive days. Exposure to dexamethasone was at least 5 or more consecutive days. PRIMARY AND SECONDARY OUTCOME MEASURES: Our primary exposure variable was concomitant exposure to dexamethasone for 5 or more days after exposure to either rivaroxaban or apixaban for 5 or more consecutive days. We used McNemar’s Χ(2) test and adjusted logistic regression to evaluate association between concomitant use of dexamethasone with either apixaban or rivaroxaban. RESULTS: McNemar’s Χ(2) test did not find a discernible association of TEE in patients concomitantly exposed to dexamethasone and a DOAC (χ(2)=0.5, df=1, p=0.48). In addition, a conditional logistic regression model did not find an increase in the risk of TEE (adjusted OR 1.15, 95% CI 0.32 to 4.18). CONCLUSION: This nested case–control study did not find evidence of an association between concomitant exposure to dexamethasone and a DOAC with an increase in risk of TEE. Due to small sample size, an association cannot be completely ruled out.
format Online
Article
Text
id pubmed-9806069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-98060692023-01-03 Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C) Kravchenko, Olga V Boyce, Richard D Gomez-Lumbreras, Ainhoa Kocis, Paul T Villa Zapata, Lorenzo Tan, Malinda Leonard, Charles E Andersen, Kathleen M Mehta, Hemalkumar Alexander, G Caleb Malone, Daniel C BMJ Open Pharmacology and Therapeutics OBJECTIVE: The goal of this work is to evaluate if there is an increase in the risk of thromboembolic events (TEEs) due to concomitant exposure to dexamethasone and apixaban or rivaroxaban. Direct oral anticoagulants (DOACs), as well as corticosteroid dexamethasone, are commonly used to treat individuals hospitalised with COVID-19. Dexamethasone induces cytochrome P450-3A4 enzyme that also metabolises DOACs apixaban and rivaroxaban. This raises a concern about possible interaction between dexamethasone and DOACs that may reduce the efficacy of the DOACs and result in an increased risk of TEE. DESIGN: We used nested case–control study design. SETTING: This study was conducted in the National COVID Cohort Collaborative (N3C), the largest electronic health records repository for COVID-19 in the USA. PARTICIPANTS: Study participants were adults over 18 years who were exposed to a DOAC for 10 or more consecutive days. Exposure to dexamethasone was at least 5 or more consecutive days. PRIMARY AND SECONDARY OUTCOME MEASURES: Our primary exposure variable was concomitant exposure to dexamethasone for 5 or more days after exposure to either rivaroxaban or apixaban for 5 or more consecutive days. We used McNemar’s Χ(2) test and adjusted logistic regression to evaluate association between concomitant use of dexamethasone with either apixaban or rivaroxaban. RESULTS: McNemar’s Χ(2) test did not find a discernible association of TEE in patients concomitantly exposed to dexamethasone and a DOAC (χ(2)=0.5, df=1, p=0.48). In addition, a conditional logistic regression model did not find an increase in the risk of TEE (adjusted OR 1.15, 95% CI 0.32 to 4.18). CONCLUSION: This nested case–control study did not find evidence of an association between concomitant exposure to dexamethasone and a DOAC with an increase in risk of TEE. Due to small sample size, an association cannot be completely ruled out. BMJ Publishing Group 2022-12-29 /pmc/articles/PMC9806069/ /pubmed/36581417 http://dx.doi.org/10.1136/bmjopen-2022-066846 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Pharmacology and Therapeutics
Kravchenko, Olga V
Boyce, Richard D
Gomez-Lumbreras, Ainhoa
Kocis, Paul T
Villa Zapata, Lorenzo
Tan, Malinda
Leonard, Charles E
Andersen, Kathleen M
Mehta, Hemalkumar
Alexander, G Caleb
Malone, Daniel C
Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
title Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
title_full Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
title_fullStr Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
title_full_unstemmed Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
title_short Drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the National COVID Cohort Collaborative (N3C)
title_sort drug–drug interaction between dexamethasone and direct-acting oral anticoagulants: a nested case–control study in the national covid cohort collaborative (n3c)
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806069/
https://www.ncbi.nlm.nih.gov/pubmed/36581417
http://dx.doi.org/10.1136/bmjopen-2022-066846
work_keys_str_mv AT kravchenkoolgav drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT boycerichardd drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT gomezlumbrerasainhoa drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT kocispault drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT villazapatalorenzo drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT tanmalinda drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT leonardcharlese drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT andersenkathleenm drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT mehtahemalkumar drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT alexandergcaleb drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c
AT malonedanielc drugdruginteractionbetweendexamethasoneanddirectactingoralanticoagulantsanestedcasecontrolstudyinthenationalcovidcohortcollaborativen3c